1 Genetic correlation and causality between smoking and 42

2 neuropsychiatric and gastrointestinal diseases

3	Jiayi Xiong ¹ , Zheng Wang ^{1,3,4} , Yuanfeng Huang ¹ , Shiyu Zhang ^{1,5} , Guang Yang ⁷ , Jiaqi Yang ¹ , Shuo
4	Gao ¹ , Tianyang Wang ^{1,5} , Jinchen Li ^{1,2,3,6*} , Guihu Zhao ^{1,3*} , Bin Li ^{1,3*}
5	
6	
7	
8	*Correspondence:
9	Jinchen Li, Guihu Zhao, Bin Li
10	Address: No.87 Xiangya Road, Changsha, Hunan, China
11	Telephone: 0731-89752068
12	E-mail address: lijinchen@csu.edu.cn, ghzhao@csu.edu.cn, lebin001@csu.edu.cn
13	
14	
15	
16	¹ Bioinformatics Centre, National Clinical Research Centre for Geriatric Disorders, Department of
17	Geriatrics, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
18	² Centre for Medical Genetics & Hunan Key Laboratory, School of Life Sciences, Central South
19	University, Changsha, Hunan 410008, China.
20	³ Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008,
21	China.
22	⁴ Hunan Key Laboratory of Molecular Precision Medicine, Xiangya Hospital, Central South University,
23	Changsha, Hunan 410008, China.
24	⁵ Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.
25	⁶ Bioinformatics Centre, Furong Laboratory, Changsha, Hunan 410008, China.
26	⁷ Department of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, Hunan,
27	China.
28	
29	
30	
31	Jiayi Xiong: xiongjy@csu.edu.cn
32	Zheng Wang: wangzheng888@csu.edu.cn
33	Yuanfeng Huang: 2025512649@qq.com
34	Shiyu Zhang: shiyuzhang0522@gmail.com
35	Guang Yang: 228111092@csu.edu.cn
36	Jiaqi Yang: 228111036@csu.edu.cn
37	Shuo Gao: <u>228111037@csu.edu.cn</u>
38	Tianyang Wang: wangtianyang@csu.edu.cn
39	
40	
41	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

42 Abstract

43 Background

44 Previous investigations have elucidated epidemiological associations linking smoking to 45 neuropsychiatric and gastrointestinal diseases, yet the underlying causal relationships remain 46 enigmatic. To shed light on this matter, we undertook a Mendelian randomisation(MR) study 47 with the aim of gauging the potential causal association between smoking and the susceptibility 48 to neuropsychiatric and gastrointestinal tract diseases.

49 Methods

50 We meticulously collected and preprocessed genome-wide association study (GWAS) data 51 encompassing smoking (280,508 cases and 180,558 controls) as well as neuropsychiatric and 52 gastrointestinal phenotypes (n = 6,681 to 87,3341). To investigate the genetic correlation 53 between smoking and diseases, we employed linkage disequilibrium score regression. We 54 further applied multi-trait analysis of GWAS to identify the shared risk single-nucleotide 55 polymorphisms (SNPs) implicated in both smoking and diseases. Pleiotropic genes were annotated by enrichment analysis. Subsequently, bidirectional MR analysis was performed to 56 57 infer causality.

58 Results

59 Our findings, supported by robust evidence derived from an expansive sample size, 60 demonstrate that smoking exerts a causal influence on merely six of these diseases, while no 61 disease was found to causally impact smoking. Intriguingly, we discovered 513 pleiotropic 62 genes enriched in pathways such as the regulation of growth and synapses, suggesting a

63	potential shared genetic basis between smoking and these diseases, leading to aberrant neural
64	development. Remarkably, among the 42 diseases scrutinized, a significant genetic correlation
65	was exclusively observed with gastroesophageal reflux disease (GRED). Furthermore, we
66	identified risk SNPs shared by smoking and GRED.
67	Conclusions
68	This study revealed the shared genetic basis and causal effects connecting smoking to
69	neuropsychiatric and gastrointestinal diseases, thereby providing novel etiological insights into
70	the role of smoking in these diseases.
71	Keywords
72	Smoking; Neuropsychiatric diseases; Gastrointestinal diseases; Mendelian randomisation;

73 Genetic correlation

74 Background

75 Tobacco utilization constitutes a momentous global public health concern and stands as a 76 paramount contributor to preventable mortality(1). Previous epidemiological inquiries have surfaced, underscoring smoking as a risk factor for many diseases, including cancers, 77 78 cardiovascular diseases, chronic obstructive pulmonary disease and so on(2). In recent years, 79 the advent of genome-wide association studies (GWAS) has engendered a burgeoning body of 80 evidence, illuminating the shared genetic underpinnings between smoking and various diseases. 81 Genetic correlation analysis, predicated on GWAS summary statistics, has unveiled the genetic 82 intertwinement linking smoking to metabolic disorders, autoimmune conditions, psychiatric 83 disorders and nervous system diseases(3–5). Beyond genetic correlation, methodologies such

84 as Mendelian randomisation (MR), which uses genetic variants as instrumental variables, have 85 been employed to discern the causal connections between lifestyle choices and diseases(6). 86 Previous MR endeavors have provided insights into the causal ramifications of smoking on 87 diseases such as lung cancer, coronary heart disease, and type 2 diabetes(7–9). 88 It is firmly established that smoking bears an association with neuropsychiatric and 89 gastrointestinal diseases, both of which bear an intimate nexus with the brain-gut axis(10,11). 90 The brain-gut axis epitomizes the bidirectional communication interlinking the central nervous 91 system and the gastrointestinal tract, constituting a pivotal arbiter for homeostasis(10). 92 Perturbations within the purview of the brain-gut axis have been inextricably implicated in an 93 assortment of ailments. For instance, patients afflicted with irritable bowel syndrome have 94 evinced perturbed interactions within the brain-gut axis(12). Although smoking has been linked 95 to both types of diseases, including Parkinson's disease(13) and colorectal cancer(14), in 96 epidemiological studies, the extent of genetic correlation and causation between smoking and 97 these diseases remains largely unknown. 98 This pioneering study represents an all-encompassing inquiry, scrutinizing the genetic 99 correlation between smoking and 42 neuropsychiatric and gastrointestinal diseases. 100 Furthermore, we unveiled the shared genetic substratum and the potential causative associations. 101 Our approach embraces an expansive and comprehensive sample size, encompassing a wide 102 spectrum of diseases, thereby fomenting a holistic comprehension of the mechanistic role

- 103 played by smoking. This distinguishing facet sets our investigation apart from previous research,
- 104 emphasising the profound genetic insights it yields.

4

105 Methods

107

106 **2.1 Study overview and data resources**

108 and gastrointestinal diseases. The GWAS summary statistics for smoking and the diseases were

Briefly, this study obtained GWAS summary statistics for smoking and 42 neuropsychiatric

- 109 sourced from publicly available databases. Specifically, the smoking GWAS data originated
- 110 from a meta-analysis encompassing the UK Biobank and the Tobacco and Genetics Consortium
- 111 datasets, focusing on smoking status (ever versus never smoked). This dataset included 280,508
- 112 individuals who were ever smokers and 180,558 individuals who were never smokers, all of
- 113 European ancestry. The data were obtained from the esteemed MRC-IEU OpenGWAS database,
- 114 with the accession ID: ukb-b-20261(accessible at https://gwas.mrcieu.ac.uk/). The GWAS data
- 115 pertaining to the 42 diseases were acquired from the MRC-IEU OpenGWAS database, the
- 116 Psychiatric Genomics Consortium (PGC), and the GWAS catalog, ensuring a sample size
- 117 exceeding 5,000. Detailed summary statistics for the GWAS data employed in this study can
- be found in Table 1.
- 119
- 120

Table 1 | Details of GWAS Summary Data Sources

Disease group	Diseases	PMID/ IEUID	N_Cases	N_Controls	N_total	Journal	Source
	ADHD	30478444	19099	34194	53293	Nature Genetics	PGC
	Anorexia nervosa	31308545	16992	55525	72517	Nature Genetics	PGC
	BD	34002096	41917	371549	413466	Nature Genetics	PGC
Psychiatric	Cannabis use disorder	33096046	14080	343726	357806	Lancet Psychiatry	PGC
diseases	Panic disorder	34737426	2248	7992	10240	Mol Psychiatry	PGC
	MDD	30718901	170756	329443	500199	Nature Neurosci	PGC
	OCD (Tourette syndrome)	30818990	4819	9488	14307	Am J Psych	PGC
	PTSD	31594949	23212	151447	174659	Nature Commun	PGC

	Schizophrenia	35396580	52017	75889	127906	Nature	PGC
	ASD	32747698	22196	32504	55420	Transl Psychiatry	GWAS Catlog
	MS	3160424	47429	68374	115803	Science	MRC-IEU
	ALS	34873335	27205	110881	138086	Nat Genet	GWAS Catlog
N	AD	35379992	85934	401577	487511	Nat Genet	GWAS Catlog
Nervous system	Lewy body dementia	33589841	2591	4027	6681	Nat Genet	GWAS Catlog
uiseases	Epilepsy	ukb-b-1600	2326	460684	463010	-	MRC-IEU
	Migraine	35115687	102084	771257	873341	Nat Genet	GWAS Catlog
	Stroke	34737426	6986	448317	455303	Nat Genet	GWAS Catlog
	PD	ieu-b-7	33674	449056	482730	Nat Genet	MRC-IEU
	Dysphagia	34737426	4601	451747	456348	Nat Genet	GWAS Catlog
	GRED	34187846	129080	473524	602604	Gut	GWAS Catlog
	Gastritis	34737426	17420	438928	456348	Nat Genet	GWAS Catlog
	GU	34737426	2413	453935	456348	Nat Genet	GWAS Catlog
	Dyspepsia	ukb-b-14814	7662	455348	463010	-	MRC-IEU
	IBS	34741163	53400	433201	486601	Nat Genet	GWAS Catlog
	CD	34737426	1342	455006	456348	Nat Genet	GWAS Catlog
	UC	34737426	2569	453779	456348	Nat Genet	GWAS Catlog
	IBD	33959723	4101	480497	484598	Nat Aging	GWAS Catlog
	Colon cancer	34737426	1482	454794	456276	Nat Genet	GWAS Catlog
	Diverticular disease	30661054	31964	419135	451099	Gut	GWAS Catlog
Controintenting	Duodenitis	34737426	2286	454062	456348	Nat Genet	GWAS Catlog
diseases	Constipation	34737426	4781	451567	456348	Nat Genet	GWAS Catlog
uistasts	Fatty liver disease	34841290	8434	770180	778614	Cell Rep Med	GWAS Catlog
	Cholelithiasis	34737426	7426	448922	456348	Nat Genet	GWAS Catlog
	Acute pancreatitis	34737426	1748	454600	456348	Nature	GWAS Catlog
	Acute appendicitis	34737426	2588	453760	456348	Nat Genet	GWAS Catlog
	Peritonitis	ukb-b-	1555	461378	462933	-	MRC-IEU
		11751					
	DU	ukb-d-K26	1291	359903	361194	-	MRC-IEU
	Polyp of colon	ukb-b-17845	2437	460573	463010	-	MRC-IEU
	Cholecystitis	ukb-d-K81	1930	359264	361194	-	MRC-IEU
	Inguinal hernia	ukb-a-549	8815	328384	337199	-	MRC-IEU
	Oesophagitis	ukb-b-19354	4931	458079	463010	-	MRC-IEU
	Primary biliary cholangitis	34033851	8021	16489	24510	-	MRC-IEU

Abbreviations: PMID, PubMed unique identifier; IEUID, the ID of the GWAS dataset in MRC IEU OpenGWAS; ADHD, attention deficit hyperactivity disorder; BD, bipolar disorder; MDD, major depressive disorder; OCD, obsessive-compulsive disorder; PTSD, post-traumatic stress disorder; ASD, autism spectrum disorders; MS, multiple sclerosis; ALS, amyotrophic lateral sclerosis; AD, Alzheimer's disease; PD, Parkinson's disease; GRED, gastroesopageal reflux disease; GU, gastric ulcer; IBS, irritable bowel syndrome; CD, Crohn's disease; UC, ulcerative colitis; IBD, inflammatory bowel disease; DU, duodenal ulcer.

121 122

123

124 2.2 Statistical Analysis

125 2.2.1 Genetic correlation analysis

To explore the genetic correlation between smoking and the aforementioned 42 diseases, we employed linkage disequilibrium score regression (LDSC)(15). This method involves regressing the product of z scores from two GWAS scans against a measure of linkage disequilibrium for each single nucleotide polymorphism (SNP). The genetic correlation results were subjected to correction for multiple testing using the rigorous Bonferroni correction, ensuring the statistical integrity of these findings. Genetic correlations with a P-value below the significance threshold $(0.05/42 = 1.25 \times 10^{-3})$ were deemed statistically significant.

133 **2.2.2 Pleiotropy analysis**

134 For diseases exhibiting significant genetic correlation with smoking according to LDSC analysis, we conducted multitrait analysis of GWAS (MTAG)(16,17) to identify shared 135 136 pleiotropic SNPs between smoking and the respective diseases. MTAG is an advanced 137 statistical fine-mapping method that leverages summary statistics from multiple GWAS to enhance the power of detecting SNPs associated with traits. It models the effect sizes of each 138 139 SNP on different traits, assuming a distribution with a variance–covariance matrix proportional 140 to the genetic correlation matrix. MTAG was executed with default parameters, and the 141 genome-wide significance threshold was set at $P < 5 \times 10^{-8}$. The results include a residual 142 correlation matrix between estimated traits, a genetic correlation matrix, and association 143 statistics for each SNP.



grounded in a multiple linear principal components regression model utilizing GWAS summary
statistics. The reference panel employed was the linkage disequilibrium structure derived from
European ancestry samples of the 1000 Genomes Project Phase 3. Genes exhibiting a false
discovery rate (FDR)-corrected P value below 0.05 in both smoking and at least one disease
were defined as pleiotropic genes.

150 Pathway enrichment analysis of the identified pleiotropic genes was performed using

151 Metascape(19). The enriched Gene Ontology (GO) terms were visually represented using the

152 clusterProfiler(20) R package.

153 **2.2.3** Causal inference analysis

To infer potential causal relationships between smoking and the diseases under investigation, 154 155 we conducted bidirectional MR analysis using the R package TwoSampleMR(21). The GWAS 156 summary statistics for smoking served as the exposure variable, while each disease was considered an outcome variable. Five different MR methods, including inverse variance 157 weighted (IVW), MR-Egger, weighted median, simple mode, and weighted mode methods, 158 159 were adopted. The IVW method was selected as the primary approach due to its high efficiency 160 and minimal assumptions(22). SNPs with an F statistic greater than 10 were included as 161 instrumental variables. The MR results were adjusted for multiple testing using the FDR method. Causal associations were reported solely for analysis without significant heterogeneity 162 163 or horizontal pleiotropy, as determined by both Cochran's Q test and the MR-PRESSO test. 164 For a significant causal relationship, we conducted a leave-one-out analysis to assess whether 165 the results were driven by any individual SNP.

166 **Results**

167 3.1 Summary information for GWAS data

- 168 The GWAS summary statistics used in this study are presented in Table 1. The smoking GWAS
- 169 data encompassed 280,508 individuals classified as ever smokers and 180,558 individuals
- 170 classified as never smokers of European ancestry, acquired from the MRC-IEU OpenGWAS
- 171 database (ID: ukb-b-20261). The GWAS data for the 42 neuropsychiatric and gastrointestinal
- 172 diseases were derived from individuals of European ancestry with sample sizes greater than
- 173 5,000 (n = 6,681 to 87,3341). (Table 1)

174 **3.2** Genetic correlation analysis

175 The genetic correlation results between smoking and these 42 diseases estimated by LDSC are 176 shown in Table 2. Following Bonferroni correction, only one disease, gastroesophageal reflux 177 disease (GRED), exhibited a statistically significant negative genetic correlation with smoking 178 $(rg = -0.226, P = 1.27 \times 10^{-7})$. The negative genetic correlation suggests the existence of shared 179 genetic factors between smoking and GRED, albeit with an inverse association. This implies 180 that certain genetic variants associated with smoking may confer a protective effect against the 181 development of GRED. This discovery holds valuable implications for our understanding of 182 the genetic determinants underlying smoking behavior and its potential impact on disease 183 susceptibility. Further investigation is warranted to unravel the precise mechanisms underlying this relationship and explore potential therapeutic avenues for GRED. 184

185

 Table 2 | Genetic Correlation Between "ever smoked" and 42 Diseases Estimated by

 LDSC

Disease group	Diseases	rg (se)	Р	Intercept (se)

	ADHD	-0.0294(0.0196)	0.1332	0.0143(0.0073)
	Anorexia nervosa	-0.083(0.0616)	0.178	0.0149(0.0173)
	BD	0.0474 (0.027)	0.0791	0.0205 (0.0126)
	Cannabis use disorder	0.0486(0.0255)	0.0564	-0.0044(0.0072)
Psychiatric diseases	Panic disorder	0.0114(0.0359)	0.7501	0.0006(0.0067)
	MDD	-0.022(0.0156)	0.1598	0.0236(0.0084)
	OCD (Tourette syndrome)	0.0136(0.0247)	0.5825	-0.0101(0.0069)
	PTSD	-0.018(0.0402)	0.6539	0.0022(0.0069)
	Schizophrenia	-0.1024(0.038)	0.007	-0.0379(0.0175)
	ASD	-0.028(0.0181)	0.1206	0.0053(0.0069)
	MS	-0.0032(0.0412)	0.938	-0.0122(0.0139)
	ALS	0.0166(0.0206)	0.4207	-0.0085(0.0072)
	AD	-0.0204(0.0176)	0.246	0.0117(0.0076)
Nervous system diseases	Lewy body dementia	-0.0392(0.0957)	0.6824	-0.0035(0.0101)
	Epilepsy	0.0926(0.1335)	0.4883	0.014(0.0155)
	Migraine	0.0388(0.0365)	0.2877	0.0023(0.0129)
	Stroke	0.0573(0.0674)	0.3953	0.014(0.0097)
	PD	-0.0166(0.0531)	0.7546	-0.013(0.014)
	Dysphagia	0.1192(0.0721)	0.0984	-0.0058(0.0095)
	GRED	-0.2259(0.0428)	1.2731E-07*	-0.0724(0.0179)
	Gastritis	0.0197(0.0565)	0.7277	0.0152(0.0101)
	GU	0.0242(0.1006)	0.8097	-0.0018(0.0095)
	Dyspepsia	-	-	-
	IBS	-0.0267(0.0193)	0.1666	0.0114(0.0081)
	CD	-0.0353(0.0636)	0.5795	0.0123(0.0104)
	UC	0.1042(0.0473)	0.0276	-0.0064(0.0104)
	IBD	0.0342(0.0739)	0.643	-0.0284(0.0136)
	Colon cancer	0.0416(0.0997)	0.6762	0.0037(0.0097)
	Diverticular disease	0.0009(0.0445)	0.9831	-0.0604(0.0158)
Gastrointestinal				
diseases	Duodenitis	-0.0966(0.0811)	0.2336	0.0211(0.0092)
uiseases	Duodenitis Constipation	-0.0966(0.0811) 0.0072(0.1639)	0.2336	0.0211(0.0092) 0.0106(0.0113)
	Duodenitis Constipation Fatty liver disease	-0.0966(0.0811) 0.0072(0.1639) -0.0457(0.0353)	0.2336 0.965 0.1954	0.0211(0.0092) 0.0106(0.0113) 0.0087(0.007)
	Duodenitis Constipation Fatty liver disease Cholelithiasis	-0.0966(0.0811) 0.0072(0.1639) -0.0457(0.0353) -0.0084(0.0513)	0.2336 0.965 0.1954 0.8703	0.0211(0.0092) 0.0106(0.0113) 0.0087(0.007) 0.0033(0.0103)
	Duodenitis Constipation Fatty liver disease Cholelithiasis Acute pancreatitis	-0.0966(0.0811) 0.0072(0.1639) -0.0457(0.0353) -0.0084(0.0513) -0.0138(0.1031)	0.2336 0.965 0.1954 0.8703 0.8933	0.0211(0.0092) 0.0106(0.0113) 0.0087(0.007) 0.0033(0.0103) 0.0065(0.0105)
	Duodenitis Constipation Fatty liver disease Cholelithiasis Acute pancreatitis Acute appendicitis	-0.0966(0.0811) 0.0072(0.1639) -0.0457(0.0353) -0.0084(0.0513) -0.0138(0.1031) -0.1265(0.0834)	0.2336 0.965 0.1954 0.8703 0.8933 0.1292	0.0211(0.0092) 0.0106(0.0113) 0.0087(0.007) 0.0033(0.0103) 0.0065(0.0105) 0.0186(0.0092)
	Duodenitis Constipation Fatty liver disease Cholelithiasis Acute pancreatitis Acute appendicitis Peritonitis	-0.0966(0.0811) 0.0072(0.1639) -0.0457(0.0353) -0.0084(0.0513) -0.0138(0.1031) -0.1265(0.0834) 0.6043(0.9047)	0.2336 0.965 0.1954 0.8703 0.8933 0.1292 0.5041	0.0211(0.0092) 0.0106(0.0113) 0.0087(0.007) 0.0033(0.0103) 0.0065(0.0105) 0.0186(0.0092) -0.0176(0.0204)
	Duodenitis Constipation Fatty liver disease Cholelithiasis Acute pancreatitis Acute appendicitis Peritonitis DU	-0.0966(0.0811) 0.0072(0.1639) -0.0457(0.0353) -0.0084(0.0513) -0.0138(0.1031) -0.1265(0.0834) 0.6043(0.9047) 0.1532(0.1353)	0.2336 0.965 0.1954 0.8703 0.8933 0.1292 0.5041 0.2574	0.0211(0.0092) 0.0106(0.0113) 0.0087(0.007) 0.0033(0.0103) 0.0065(0.0105) 0.0186(0.0092) -0.0176(0.0204) 0.003(0.013)
	Duodenitis Constipation Fatty liver disease Cholelithiasis Acute pancreatitis Acute appendicitis Peritonitis DU Polyp of colon	-0.0966(0.0811) 0.0072(0.1639) -0.0457(0.0353) -0.0084(0.0513) -0.0138(0.1031) -0.1265(0.0834) 0.6043(0.9047) 0.1532(0.1353)	0.2336 0.965 0.1954 0.8703 0.8933 0.1292 0.5041 0.2574	0.0211(0.0092) 0.0106(0.0113) 0.0087(0.007) 0.0033(0.0103) 0.0065(0.0105) 0.0186(0.0092) -0.0176(0.0204) 0.003(0.013) -0.0002(0.0147)
	Duodenitis Constipation Fatty liver disease Cholelithiasis Acute pancreatitis Acute appendicitis Peritonitis DU Polyp of colon Cholecystitis	-0.0966(0.0811) 0.0072(0.1639) -0.0457(0.0353) -0.0084(0.0513) -0.0138(0.1031) -0.1265(0.0834) 0.6043(0.9047) 0.1532(0.1353) - -0.1388(0.1194)	0.2336 0.965 0.1954 0.8703 0.8933 0.1292 0.5041 0.2574 - 0.2451	0.0211(0.0092) 0.0106(0.0113) 0.0087(0.007) 0.0033(0.0103) 0.0065(0.0105) 0.0186(0.0092) -0.0176(0.0204) 0.003(0.013) -0.0002(0.0147) 0.0272(0.0129)
	Duodenitis Constipation Fatty liver disease Cholelithiasis Acute pancreatitis Acute appendicitis Peritonitis DU Polyp of colon Cholecystitis Inguinal hernia	-0.0966(0.0811) 0.0072(0.1639) -0.0457(0.0353) -0.0084(0.0513) -0.0138(0.1031) -0.1265(0.0834) 0.6043(0.9047) 0.1532(0.1353) - -0.1388(0.1194) 0.004(0.0682)	0.2336 0.965 0.1954 0.8703 0.8933 0.1292 0.5041 0.2574 - 0.2451 0.9538	0.0211(0.0092) 0.0106(0.0113) 0.0087(0.007) 0.0033(0.0103) 0.0065(0.0105) 0.0186(0.0092) -0.0176(0.0204) 0.003(0.013) -0.0002(0.0147) 0.0272(0.0129) 0.0123(0.0133)
	Duodenitis Constipation Fatty liver disease Cholelithiasis Acute pancreatitis Acute appendicitis Peritonitis DU Polyp of colon Cholecystitis Inguinal hernia	-0.0966(0.0811) 0.0072(0.1639) -0.0457(0.0353) -0.0084(0.0513) -0.0138(0.1031) -0.1265(0.0834) 0.6043(0.9047) 0.1532(0.1353) - -0.1388(0.1194) 0.004(0.0682) 0.218(0.1180)	0.2336 0.965 0.1954 0.8703 0.8933 0.1292 0.5041 0.2574 - 0.2451 0.9538 0.0668	0.0211(0.0092) 0.0106(0.0113) 0.0087(0.007) 0.0033(0.0103) 0.0065(0.0105) 0.0186(0.0092) -0.0176(0.0204) 0.003(0.013) -0.0002(0.0147) 0.0272(0.0129) 0.0123(0.0133) 0.0053(0.0136)

Abbreviations: LDSC, linkage disequilibrium score regression; rg, genetic correlation estimate; se, standard error; ADHD, attention deficit hyperactivity disorder; BD, bipolar disorder; MDD, major depressive disorder; OCD, obsessive-compulsive disorder; PTSD, post-traumatic stress disorder; ASD, autism spectrum disorders; MS, multiple sclerosis; ALS, amyotrophic lateral sclerosis; AD, Alzheimer's disease; PD, Parkinson's disease; GRED, gastroesopageal reflux disease; GU, gastric ulcer; IBS, irritable bowel syndrome; CD, Crohn's disease; UC, ulcerative colitis; IBD, inflammatory bowel disease; DU, duodenal ulcer.

*P value reached the Bonferroni-corrected significance level P < $1.25 \times 10-3$ (0.05/42)

186

187 **3.2 Pleiotropy analysis**

188 Given that only GRED showed a significant genetic correlation with smoking, we proceeded

to perform MTAG between the GWAS data for smoking and GRED. A total of 971,487 SNPs

190 were included in the meta-analysis by MTAG. Among them, 358 SNPs reached the genome-

191 wide significance level ($P < 5 \times 10^{-8}$) in the MTAG smoking analysis, indicating their status as

192 pleiotropic SNPs shared by smoking and GRED (detailed information provided in Additional

193 file: Supplementary Table S1).

194 Using MAGMA, we identified 513 pleiotropic genes associated with both smoking and at least

195 one disease after excluding genes on chromosome 6 (Additional file: Supplementary Table S2).

196 These genes are considered candidate pleiotropic genes that are shared between smoking and

197 multiple diseases, indicating their potential role in modulating the relationship between

198 smoking and these diseases. Notably, genes such as CRHR1, KANSL1, PLEKHM1, STH and

199 WNT3 on chromosome 17 as well as MSRA on chromosome 8 were identified as pleiotropic

200 genes in at least 5 diseases respectively.

201 Pathway enrichment analysis of the identified pleiotropic genes revealed significant enrichment

in multiple GO terms (Figure 1; Additional file: Supplementary Table S3-S5), encompassing

203 processes such as cell projection morphogenesis, presynapse, and protein domain specific

binding. Importantly, our findings indicate that smoking interacts with these signaling pathways,

- 205 contributing to the occurrence of 42 neuropsychiatric and gastrointestinal diseases. Remarkably,
- 206 our results align with previous literature, substantiating the consistent relationship between
- smoking and these diseases at a molecular level.



208

Fig. 1 Enrichment maps of pleiotropic genes for smoking and 42 diseases. A GO biological
process enrichment bar chart. B GO cellular component enrichment bar chart. C GO molecular function
enrichment bar chart. From panels A to C, the X-axis is -log10(P), and the Y-axis is the GO term. The
colour represents the enriched significance.

213

214 **3.3** Causal inference analysis

- 215 Mendelian randomisation analysis suggested potential causal relationships between smoking
- and several diseases. Overall, smoking demonstrated significant positive causal effects on 6
- 217 diseases after adjusting for multiple testing using the Benjamini–Hochberg (BH) method for P

218	value adjustment (Figure 2; Additional file: Supplementary Table S6), including ulcerative
219	colitis (UC) (IVW: odds ratio [OR] = 6.84, 95% confidence interval [CI] 2.23-20.99, P < 0.001),
220	inflammatory bowel disease (IBD) (IVW: OR = 1.01, 95% CI 1.00-1.02, P = 0.003), gastritis
221	(IVW: OR = 1.79, 95% CI 1.13-2.82, P = 0.013), post-traumatic stress disorder (PTSD) (IVW:
222	OR = 1.97, 95% CI 1.14-3.41, P = 0.016), cholelithiasis (IVW: OR = 2.03, 95% CI 1.08-3.80,
223	P = 0.027) and epilepsy (IVW: OR = 1.01, 95% CI 1.00-1.01, P = 0.035). Although Crohn's
224	disease (CD) and primary biliary cholangitis did not reach the 0.05 significance threshold, they
225	also exhibited positive causal tendencies. It is important to note that while smoking showed
226	positive causal effects on attention-deficit/hyperactivity disorder (ADHD), cannabis use
227	disorder, major depressive disorder (MDD), bipolar disorder (BD), and GRED, further
228	verification is required for this causal relationship, as indicated by the heterogeneity test and
229	MR-PRESSO test P values being <0.05, suggesting the presence of pleiotropy and less reliable
230	MR results.

Outcome	Method	nSNP		OR (95% CI)	Р
Psychiatric diseases			i		
ADHD	IVW	65		16.71 (8.06 to 34.66)	<0.0001
Anorexia nervosa	IVW	66		 1.83 (0.82 to 4.10) 	0.1429
BD	IVW	67		3.05 (1.61 to 5.79)	0.0006
Cannabis use disorder	IVW	67		18.17 (8.56 to 38.53)	<0.0001
Panic disorder	IVW	67	<	0.63 (0.15 to 2.63)	0.5309
MDD	IVW	65		2.30 (1.66 to 3.18)	<0.0001
OCD	IVW	66 1		0.37 (0.10 to 1.33)	0.1276
PTSD	IVW	67		 1.97 (1.14 to 3.41) 	0.0158
Schizophrenia	IVW	67		 1.62 (0.77 to 3.39) 	0.2032
Nervous system disease	s				
ASD	IVW	66	++	 1.85 (0.94 to 3.66) 	0.0760
MS	IVW	63		 1.66 (0.81 to 3.37) 	0.1636
ALS	IVW	65		0.81 (0.50 to 1.30)	0.3780
AD	IVW	65	••••••••••••••••••••••••••••••••••••	0.71 (0.47 to 1.07)	0.1048
Lewy body dementia	IVW	63	·	 0.45 (0.11 to 1.85) 	0.2695
Epilepsy	IVW	64	•	1.01 (1.00 to 1.01)	0.0347
Migraine	IVW	67		0.88 (0.55 to 1.40)	0.5870
Stroke	IVW	65		 1.69 (0.85 to 3.36) 	0.1379
PD	IVW	64		0.49 (0.19 to 1.26)	0.1369
Gastrointestinal diseases	5				
Dysphagia	IVW	65	H	2.00 (0.91 to 4.42)	0.0860
GRED	IVW	33		2.26 (1.21 to 4.22)	0.0108
Gastritis	IVW	65	·	 1.79 (1.13 to 2.82) 	0.0129
GU	IVW	65		 1.11 (0.36 to 3.42) 	0.8517
Dyspepsia	IVW	67	•	1.00 (0.99 to 1.01)	0.6425
IBS	IVW	67		 1.29 (0.87 to 1.92) 	0.2040
CD	IVW	65		4.31 (1.00 to 18.61)	0.0500
UC	IVW	65		6.84 (2.23 to 20.99)	0.0008
IBD	IVW	67		1.01 (1.00 to 1.02)	0.0026
Colon cancer	IVW	65		 3.52 (0.87 to 14.14) 	0.0765
Diverticular disease	IVW	67	÷	1.01 (0.98 to 1.04)	0.3919
Duodenitis	IVW	65		1.53 (0.45 to 5.19)	0.4993
Constipation	IVW	65		 0.57 (0.21 to 1.55) 	0.2715
Fatty liver disease	IVW	65		 1.81 (0.95 to 3.45) 	0.0730
Cholelithiasis	IVW	65		2.03 (1.08 to 3.80)	0.0269
Acute pancreatitis	IVW	65		 0.56 (0.16 to 2.03) 	0.3799
Acute appendicitis	IVW	65	• • • • • • • • • • • • • • • • • • •	 0.84 (0.29 to 2.48) 	0.7561
Peritonitis	IVW	57	•	1.00 (1.00 to 1.01)	0.7005
DU	IVW	66	÷	1.00 (0.99 to 1.01)	0.8545
Polyp of colon	IVW	67	•	1.00 (1.00 to 1.01)	0.1265
Cholecystitis	IVW	66	•	1.00 (1.00 to 1.01)	0.1407
Inguinal hernia	IVW	66	+	1.00 (0.98 to 1.01)	0.7753
Oesophagitis	IVW	67	•	1.01 (1.00 to 1.02)	0.1127
Primary biliary cholangitis	IVW	27		8.70 (0.85 to 89.42)	0.0688
			0.8 1 1.3		

232

Protective factors Risk factors

233 Fig. 2 MR estimates for the effect of "ever smoked" on 42 diseases. Estimates were derived by the 234 inverse-variance weighted method. Reported P-values were adjusted for multiple testing using the Benjamini-235 Hochberg procedure. The solid lines represent 95% CI; CI, confidence interval; OR, odds ratio. ADHD, attention 236 deficit hyperactivity disorder; BD, bipolar disorder; MDD, major depressive disorder; OCD, obsessive-compulsive 237 disorder; PTSD, post-traumatic stress disorder; ASD, autism spectrum disorders; MS, multiple sclerosis; ALS, 238 amyotrophic lateral sclerosis; AD, Alzheimer's disease; PD, Parkinson's disease; GRED, gastroesopageal reflux 239 disease; GU, gastric ulcer; IBS, irritable bowel syndrome; CD, Crohn's disease; UC, ulcerative colitis; IBD, 240 inflammatory bowel disease; DU, duodenal ulcer.

241

242 On the other hand, no disease demonstrated a significant causal effect on smoking after

243	adjusting for multiple testing (Figure 3; Additional file: Supplementary Table S7). Although
244	BP (IVW: OR = 0.99, 95% CI 0.98-1.00, P = 0.018) presented a negative causal relationship
245	with smoking, in the MR analysis, the result was less reliable due to the detection of horizontal
246	pleiotropy. Leave-one-out analysis indicated that the causal relationships were not driven by
247	any single SNP.

248

Exposure	Method	nSNP		OR (95% CI)	Р
Psychiatric diseases			1		
ADHD	IVW	9	-	0.98 (0.96 to 1.00)	0.0893
Anorexia nervosa	IVW	7		0.99 (0.98 to 1.01)	0.5991
BD	IVW	50		0.99 (0.98 to 1.00)	0.0177
Schizophrenia	IVW	5		1.00 (0.97 to 1.04)	0.8385
Nervous system diseases					
MS	IVW	39	•	1.00 (1.00 to 1.01)	0.4461
ALS	IVW	7	÷	1.00 (0.99 to 1.01)	0.8750
AD	IVW	17		0.99 (0.99 to 1.00)	0.1104
Gastrointestinal diseases					
IBS	IVW	5	H	1.04 (0.89 to 1.22)	0.6071
CD	IVW	6		1.00 (1.00 to 1.00)	0.8992
UC	IVW	8	+	1.00 (0.99 to 1.00)	0.5062
Cholelithiasis	IVW	11		1.00 (1.00 to 1.00)	0.8021
Primary biliary cholangitis	IVW	17	•	1.00 (1.00 to 1.01)	0.4904
Inguinal hernia	IVW	10	0.8 1 1.3	1.16 (0.89 to 1.53)	0.2738

249

Protective factors Risk factors

Fig. 3 MR estimates for the effect of 42 diseases on "ever smoked". Estimates were derived by the
inverse-variance weighted method. Reported P-values were adjusted for multiple testing using the BenjaminiHochberg procedure. The solid lines represent 95% CI; CI, confidence interval; OR, odds ratio. ADHD, attention
deficit hyperactivity disorder; BD, bipolar disorder; MS, multiple sclerosis; ALS, amyotrophic lateral sclerosis; AD,
Alzheimer's disease; IBS, irritable bowel syndrome; CD, Crohn's disease; UC, ulcerative colitis.

255

256 **Discussion**

This investigation presents the most extensive compilation of publicly accessible GWAS data,
enabling a comprehensive characterization of the genetic associations, pleiotropy and causality
underlying smoking and neuropsychiatric and gastrointestinal diseases. Notably, our findings

unveil a significant genetic correlation between smoking and GRED. Moreover, our researchidentifies six diseases in which smoking exhibits a causal relationship.

262 In this study, we report, for the first time, that among the 42 neuropsychiatric and 263 gastrointestinal diseases examined, only GERD exhibits a significant genetic association with 264 smoking. This finding aligns with previous epidemiological evidence suggesting a connection 265 between smoking and GRED (23-25). The genetic correlation between smoking and GRED suggests the presence of shared genetic factors, indicating potential associations between the 266 267 two. However, further investigation is required to determine the precise mechanisms underlying 268 these relationships. Our pleiotropy analysis using MTAG revealed 358 SNPs jointly associated 269 with both smoking and GRED. However, we found no evidence supporting a significant causal 270 relationship between smoking and GRED in our MR analysis after horizontal pleiotropy and 271 heterogeneity tests. This study boasts a substantially larger sample size for GERD, 272 encompassing 129,080 cases and 473,524 controls, totaling 602,604 samples. This heightened 273 sample size enhances the statistical power of our results, rendering this study's conclusions 274 more reliable and compelling in refuting the previous finding(25) of a causal effect of smoking 275 on GERD (71,522 cases and 261,079 controls) and supporting the notion that the genetic 276 association is more likely attributable to pleiotropy.

Furthermore, we observed a potential genetic link between smoking and psychiatric disorders such as schizophrenia, which corroborates the findings of previous studies(26,27). It is noteworthy that both our study, conducted within a European population, and previous studies conducted in East Asian populations did not find a significant causal relationship between smoking and schizophrenia(28). Moreover, recent research suggests that the potential genetic

association between smoking and schizophrenia may stem from a local genetic correlation at
15q25(29). This discovery contributes to the mounting evidence supporting a genetic link
between smoking and schizophrenia arising from specific loci rather than causal effects.

285 Additionally, pathway clustering analysis revealed that the 513 pleiotropic genes shared 286 between smoking and the 42 diseases were enriched for pathways related to growth regulation 287 and synaptic function. This enrichment suggests that smoking may be implicated in disease development by influencing neural and developmental processes. The enriched 288 neurodevelopmental pathways imply that smoking could disrupt crucial growth regulators 289 290 during neural maturation, thereby affecting disease risk. The synaptic pathways indicate that smoking might influence neurotransmitter signaling and synaptic plasticity, thereby impacting 291 292 disease pathogenesis. By connecting smoking-associated genes to established disease pathways, 293 our integrative analysis yields new biological insights distinct from previous observational 294 studies. Nonetheless, experimental validations are necessary to confirm the functional roles of 295 the identified genes and pathways in mediating the relationships between smoking and diseases. 296 Our MR analysis provides compelling evidence of causal relationships between smoking and several diseases, including UC, IBD, gastritis, PTSD, cholelithiasis, and epilepsy. These 297 298 findings underscore the unique strength of our study in comparison to previous research. 299 Consistent with prior studies, our MR analysis verifies the causal relationship between smoking 300 and cholelithiasis, IBD, and gastritis(30). Furthermore, our results align with a meta-analysis 301 reporting an increased risk of gallbladder disease associated with smoking(31). However, our 302 study diverges from previous research by furnishing robust genetic evidence that smoking does 303 not causally affect gastric and duodenal ulcers, irritable bowel syndrome, or CD. Our MR

analysis, with its larger sample size and rigorous statistical corrections, offers novel genetic insights into the causal effects of smoking on diseases. In contrast, we did not detect significant causal effects of the diseases on smoking after multiple testing correction. These null associations indicate that while smoking may influence disease risk, the reverse direction of disease liability contributing to smoking initiation is not supported by genetic evidence. Further studies are warranted to replicate these findings and unravel the biological mechanisms underlying the identified causal effects.

311 Several limitations merit attention in this study. First, the GWAS data primarily pertain to 312 European ancestry populations and may not be fully generalizable to other ethnic groups. Future 313 investigations involving more diverse populations are imperative to validate the findings. 314 Second, the causal inferences derived from MR analysis require further experimental validation 315 to elucidate the specific molecular mechanisms. In addition, the GWAS samples for smoking 316 and diseases may have partial overlap, which could introduce bias and lead to inflated causal 317 associations. Although we endeavored to maximize the independence between exposure and 318 outcome samples during MR analysis, it is crucial to consider the potential sample overlap 319 when interpreting the causal effects. Additionally, the study may be subject to limitations 320 inherent to the statistical methodology, making it challenging to determine weaker causal 321 relationships between smoking and certain diseases. Our findings call for further research into 322 biological pathways to comprehensively delineate the causality between smoking and various 323 diseases, ultimately advancing precision medicine. Despite these limitations, our study offers 324 comprehensive insights into the potential causal effects of smoking on a wide range of disease 325 endpoints within both the neuropsychiatric and gastrointestinal systems. Further rigorous

326 investigations in the future can aid in validating and expanding upon the findings presented

327 here.

328 Conclusions

- 329 Overall, by integrating multiple genetic approaches, this study unveils the shared genetics and
- 330 potential pathogenic effects linking smoking to neuropsychiatric and gastrointestinal diseases,
- 331 providing crucial insights for subsequent research in this domain. Moreover, these findings hold
- 332 promise for advancing clinical translational applications that aim to elucidate the intricate
- 333 relationships between smoking and various diseases.

334 List of Abbreviations

- 335 MR: Mendelian randomisation
- 336 **GWAS:** Genome-wide association study
- **337 SNP:** Single-nucleotide polymorphisms
- **338 GRED:** Gastroesophageal reflux disease
- **339 PGC:** The Psychiatric Genomics Consortium
- 340 LDSC: The linkage disequilibrium score regression
- **MTAG:** Multitrait analysis of GWAS
- 342 **FDR:** False discovery rate
- **343 GO:** Gene Ontology
- 344 **IVW:** Inverse variance weighted
- 345 BH: Benjamini–Hochberg
- 346 **OR:** Odds ratio

- 347 CI: Confidence interval
- 348 UC: Ulcerative colitis
- **349 IBD:** Inflammatory bowel disease
- 350 PTSD: Post-traumatic stress disorder
- 351 **CD:** Crohn's disease
- 352 ADHD: Attention-deficit/hyperactivity disorder
- 353 MDD: Major depressive disorder
- **BD:** Bipolar disorder

355

356 **Declarations**

357 Ethics approval and consent to participate

358 Not applicable.

359 Consent for publication

360 Not applicable.

361 Availability of data and materials

362 The GWAS datasets supporting the conclusions of this article are available in the GWAS

363 Catalog (https://www.ebi.ac.uk/gwas/), the Psychiatric Genomics Consortium

- $\label{eq:constraint} 364 \quad (https://www.med.unc.edu/pgc/) \quad and \quad the \quad MRC-IEU \quad OpenGWAS \quad database$
- 365 (https://gwas.mrcieu.ac.uk/). The Migraine GWAS dataset provided by Hautakangas et al.(32)
- 366 can be obtained by contacting the International Headache Genetics Consortium. Data analysis

367	was	performed	using	R	version	4.2.2.	LDSC	(https://github.com/bulik/ldsc/),	MTAG
-----	-----	-----------	-------	---	---------	--------	------	-----------------------------------	------

- 368 (https://github.com/JonJala/mtag/) and MAGMA(http://ctglab.nl/software/magma) were used
- 369 for analysis, and Metascape (https://metascape.org/) was used for gene ontology enrichment
- analysis. This study was not preregistered.

371 **Competing interests**

372 The authors declare that they have no competing interests.

373 Funding

- 374 This study was supported by the Fundamental Research Funds for National Key R&D Program
- of China (2021YFC2502100), the National Natural Science Foundation of China (82001362),
- the Hunan Youth Science and Technology Innovation Talent Project (2022RC1070), and the
- 377 Natural Science Foundation of Hunan Province in China (2021JJ31070).
- 378 Authors' Information
- 379 Affiliations
- 380 Bioinformatics Centre, National Clinical Research Centre for Geriatric Disorders, Department
- 381 of Geriatrics, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
- Jiayi Xiong, Zheng Wang, Yuanfeng Huang, Shiyu Zhang, Jiaqi Yang, Shuo Gao, Tianyang
- 383 Wang, Jinchen Li, Guihu Zhao & Bin Li
- 384 Centre for Medical Genetics & Hunan Key Laboratory, School of Life Sciences, Central
- 385 South University, Changsha, Hunan 410008, China.
- 386 Jinchen Li
- 387 Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan

- 388 410008, China.
- 389 Zheng Wang, Jinchen Li, Guihu Zhao & Bin Li
- 390 Hunan Key Laboratory of Molecular Precision Medicine, Xiangya Hospital, Central South
- 391 University, Changsha, Hunan 410008, China.
- 392 Zheng Wang
- 393 Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.
- 394 Shiyu Zhang & Tianyang Wang
- 395 Bioinformatics Centre, Furong Laboratory, Changsha, Hunan 410008, China.
- 396 Jinchen Li
- 397 Department of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008,
- 398 Hunan, China.
- 399 Guang Yang

400 Contributions

- 401 JCL, GHZ and BL designed and supervised the study, while JYX performed the majority of the
- 402 analysis and drafted the manuscript. BL provided mentorship, and all authors contributed to the
- 403 study, interpreted the findings, and reviewed the manuscript. The final version of the
- 404 manuscript was approved by all authors before publication.
- 405 Corresponding author
- 406 Correspondence to: Jinchen Li, Guihu Zhao, Bin Li
- 407 Address: No.87 Xiangya Road, Changsha, Hunan, China
- 408 Telephone: 0731-89752068
- 409 E-mail address: lijinchen@csu.edu.cn, ghzhao@csu.edu.cn, lebin001@csu.edu.cn

410 Acknowledgements

- 411 We are grateful for resources from the High-Performance Computing Centre of Central South
- 412 University and we would like to thank the International Headache Genetics Consortium for
- 413 providing us with the migraine GWAS summary data, the GWAS Catlog and the PGC and the
- 414 MRC-IEU OpenGWAS database for providing other GWAS datasets.

415 **References**

- 416 1. Cornelius ME, Loretan CG, Jamal A, Lynn BCD, Mayer M, Alcantara IC, et al. Tobacco
- 417 Product Use Among Adults United States, 202. 2023;72(18).
- 418 2. Kamceva G, Arsova-Sarafinovska Z, Ruskovska T, Zdravkovska M, Kamceva-Panova L,
- 419 Stikova E. Cigarette Smoking and Oxidative Stress in Patients with Coronary Artery Disease.
- 420 Open Access Maced J Med Sci. 2016 Oct 28;4(4):636–40.
- 421 3. Barkhuizen W, Dudbridge F, Ronald A. Genetic overlap and causal associations between
- 422 smoking behaviours and mental health. Sci Rep. 2021 Jul 21;11(1):14871.
- 423 4. Papoutsopoulou S, Satsangi J, Campbell BJ, Probert CS. Review article: impact of cigarette
- 424 smoking on intestinal inflammation—direct and indirect mechanisms. Alimentary
- 425 Pharmacology & Therapeutics. 2020;51(12):1268–85.
- 426 5. Winsvold BS, Harder AVE, Ran C, Chalmer MA, Dalmasso MC, Ferkingstad E, et al. Cluster
- 427 Headache Genomewide Association Study and Meta-Analysis Identifies Eight Loci and
- 428 Implicates Smoking as Causal Risk Factor. Ann Neurol. 2023 Jul 24;10.1002/ana.26743.
- 429 6. Vandebergh M, Goris A. Smoking and multiple sclerosis risk: a Mendelian randomization

430 study. J Neuro	ol. 2020 Oct;267(10):3083–91.
--------------------	-------------------------------

431	7.	Larsson SC, Carter P, Kar S, Vithayathil M, Mason AM, Michaëlsson K, et al. Smoking,
432		alcohol consumption, and cancer: A mendelian randomisation study in UK Biobank and
433		international genetic consortia participants. PLoS Med. 2020 Jul 23;17(7):e1003178.
434	8.	Larsson SC, Mason AM, Bäck M, Klarin D, Damrauer SM, Million Veteran Program, et al.
435		Genetic predisposition to smoking in relation to 14 cardiovascular diseases. European Heart
436		Journal. 2020 Sep 14;41(35):3304–10.
437	9.	Larsson SC, Burgess S. Appraising the causal role of smoking in multiple diseases: A
438		systematic review and meta-analysis of Mendelian randomization studies. eBioMedicine. 2022
439		Aug;82:104154.
440	10.	Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, et al. The
440 441	10.	Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, et al. The Microbiota-Gut-Brain Axis. Physiological Reviews. 2019 Oct 1;99(4):1877–2013.
440 441 442	10. 11.	Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, et al. The Microbiota-Gut-Brain Axis. Physiological Reviews. 2019 Oct 1;99(4):1877–2013. Gong W, Guo P, Li Y, Liu L, Yan R, Liu S, et al. Role of the Gut-Brain Axis in the Shared
440 441 442 443	10. 11.	Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, et al. The Microbiota-Gut-Brain Axis. Physiological Reviews. 2019 Oct 1;99(4):1877–2013. Gong W, Guo P, Li Y, Liu L, Yan R, Liu S, et al. Role of the Gut-Brain Axis in the Shared Genetic Etiology Between Gastrointestinal Tract Diseases and Psychiatric Disorders: A
440 441 442 443 444	10.	Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, et al. The Microbiota-Gut-Brain Axis. Physiological Reviews. 2019 Oct 1;99(4):1877–2013. Gong W, Guo P, Li Y, Liu L, Yan R, Liu S, et al. Role of the Gut-Brain Axis in the Shared Genetic Etiology Between Gastrointestinal Tract Diseases and Psychiatric Disorders: A Genome-Wide Pleiotropic Analysis. JAMA Psychiatry. 2023 Apr 1;80(4):360.
440 441 442 443 444 445	10.11.12.	Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, et al. The Microbiota-Gut-Brain Axis. Physiological Reviews. 2019 Oct 1;99(4):1877–2013. Gong W, Guo P, Li Y, Liu L, Yan R, Liu S, et al. Role of the Gut-Brain Axis in the Shared Genetic Etiology Between Gastrointestinal Tract Diseases and Psychiatric Disorders: A Genome-Wide Pleiotropic Analysis. JAMA Psychiatry. 2023 Apr 1;80(4):360. Margolis KG, Cryan JF, Mayer EA. The Microbiota-Gut-Brain Axis: From Motility to Mood.
440 441 442 443 444 445 446	10.11.12.	 Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, et al. The Microbiota-Gut-Brain Axis. Physiological Reviews. 2019 Oct 1;99(4):1877–2013. Gong W, Guo P, Li Y, Liu L, Yan R, Liu S, et al. Role of the Gut-Brain Axis in the Shared Genetic Etiology Between Gastrointestinal Tract Diseases and Psychiatric Disorders: A Genome-Wide Pleiotropic Analysis. JAMA Psychiatry. 2023 Apr 1;80(4):360. Margolis KG, Cryan JF, Mayer EA. The Microbiota-Gut-Brain Axis: From Motility to Mood. Gastroenterology. 2021 Apr;160(5):1486–501.

448 and the risk of Parkinson disease: A 65-year follow-up of 30,000 male British doctors.

449 Neurology. 2020 May 19;94(20):e2132–8.

450	14.	Botteri E, Borroni E, Sloan EK, Bagnardi V, Bosetti C, Peveri G, et al. Smoking and Colorectal
451		Cancer Risk, Overall and by Molecular Subtypes: A Meta-Analysis. Am J Gastroenterol. 2020
452		Dec;115(12):1940–9.
453	15.	Schizophrenia Working Group of the Psychiatric Genomics Consortium, Bulik-Sullivan BK,
454		Loh PR, Finucane HK, Ripke S, Yang J, et al. LD Score regression distinguishes confounding
455		from polygenicity in genome-wide association studies. Nat Genet. 2015 Mar;47(3):291–5.
456	16.	Turley P, Walters RK, Maghzian O, Okbay A, Lee JJ, Fontana MA, et al. Multi-trait analysis
457		of genome-wide association summary statistics using MTAG. Nat Genet. 2018 Feb;50(2):229-
458		37.
459	17.	Zeng R, Jiang R, Huang W, Wang J, Zhang L, Ma Y, et al. Dissecting shared genetic
460		architecture between obesity and multiple sclerosis. eBioMedicine. 2023 Jul;93:104647.
461	18.	de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of
462		GWAS data. PLoS Comput Biol. 2015 Apr 17;11(4):e1004219.

463 19. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape
464 provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun.
465 2019 Apr 3;10(1):1523.

466 20. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R Package for Comparing Biological
467 Themes Among Gene Clusters. OMICS: A Journal of Integrative Biology. 2012

468 May;16(5):284–7.

469	21.	Burgess S, Butterworth A, Thompson SG. Mendelian Randomization Analysis With Multiple
470		Genetic Variants Using Summarized Data. Genet Epidemiol. 2013 Nov;37(7):658-65.
471	22.	Lee CH, Cook S, Lee JS, Han B. Comparison of Two Meta-Analysis Methods: Inverse-
472		Variance-Weighted Average and Weighted Sum of Z-Scores. Genomics Inform.
473		2016;14(4):173.
474	23.	Sharma P. Barrett Esophagus: A Review. JAMA. 2022 Aug 16;328(7):663.
475	24.	Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal Reflux Disease: A Review. JAMA.
476		2020 Dec 22;324(24):2536.
477	25.	Yuan S, Larsson SC. Adiposity, diabetes, lifestyle factors and risk of gastroesophageal reflux
478		disease: a Mendelian randomization study. Eur J Epidemiol. 2022 Jul;37(7):747-54.
479	26.	Hahad O, Daiber A, Michal M, Kuntic M, Lieb K, Beutel M, et al. Smoking and
480		Neuropsychiatric Disease-Associations and Underlying Mechanisms. IJMS. 2021 Jul
481		6;22(14):7272.

- 482 27. Hartz SM, Horton AC, Hancock DB, Baker TB, Caporaso NE, Chen LS, et al. Genetic
 483 correlation between smoking behaviors and schizophrenia. Schizophrenia Research. 2018
 484 Apr;194:86–90.
- 28. Chen J, Chen R, Xiang S, Li N, Gao C, Wu C, et al. Cigarette smoking and schizophrenia:
 Mendelian randomisation study. Br J Psychiatry. 2021 Feb;218(2):98–103.

487	29.	Gerring ZF, Thorp JG, Gamazon ER, Derks EM. A Local Genetic Correlation Analysis
488		Provides Biological Insights Into the Shared Genetic Architecture of Psychiatric and Substance
489		Use Phenotypes. Biological Psychiatry. 2022 Oct;92(7):583-91.
490	30.	Yuan S, Chen J, Ruan X, Sun Y, Zhang K, Wang X, et al. Smoking, alcohol consumption, and
491		24 gastrointestinal diseases: Mendelian randomization analysis. eLife. 12:e84051.
492	31.	Aune D, Vatten LJ, Boffetta P. Tobacco smoking and the risk of gallbladder disease. Eur J
493		Epidemiol. 2016 Jul;31(7):643–53.
494	32.	Hautakangas H, Winsvold BS, Ruotsalainen SE, Bjornsdottir G, Harder AVE, Kogelman LJA,
495		et al. Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-
496		specific risk alleles. Nat Genet. 2022 Feb;54(2):152-60.
497		
498		
499		
500		
501		
502		
503		
504 505		
505		
507		
508		
509		
510		
511		
512		
513		
514		



Outcome	Method	nSNP			OR (95% CI)	Р
Psychiatric diseases			i			
ADHD	IVW	65			16.71 (8.06 to 34.66)	< 0.0001
Anorexia nervosa	IVW	66			1.83 (0.82 to 4.10)	0.1429
BD	IVW	67			3.05 (1.61 to 5.79)	0.0006
Cannabis use disorder	IVW	67			18.17 (8.56 to 38.53)	< 0.0001
Panic disorder	IVW	67			0.63 (0.15 to 2.63)	0.5309
MDD	IVW	65			2.30 (1.66 to 3.18)	< 0.0001
OCD	IVW	66 I	+		0.37 (0.10 to 1.33)	0.1276
PTSD	IVW	67		→	1.97 (1.14 to 3.41)	0.0158
Schizophrenia	IVW	67			1.62 (0.77 to 3.39)	0.2032
Nervous system diseases	5					
ASD	IVW	66			1.85 (0.94 to 3.66)	0.0760
MS	IVW	63			1.66 (0.81 to 3.37)	0.1636
ALS medRxiv preprint doi: https://doi.org/10.11	101/2020 5 09 2430	71 65 his vers	ion posted May 10, 2024. The con	wright holder for this pre	0.81 (0.50 to 1.30)	0.3780
(which was not certified by peer revie	ew) is the author/function is made available unc	ler, who has gi ler G C-BY 4.	anted medRxiv a license to display 0 International license .	y the preprint in perpetu	0.71 (0.47 to 1.07)	0.1048
Lewy body dementia	IVW	63 1			0.45 (0.11 to 1.85)	0.2695
Epilepsy	IVW	64			1 01 (1 00 to 1 01)	0.0347
Migraine	IVW/	67			0.88 (0.55 to 1.40)	0.5870
Stroke	IV/W/	65			1.69 (0.85 to 3.36)	0 1379
PD	1\/\//	64	HE		0.49 (0.19 to 1.26)	0.1369
Gastrointestinal diseases		04	~		0.40 (0.10 (0 1.20)	0.1000
Dysphagia	11/14/	65			2 00 (0 91 to 4 42)	0.0860
	11/10/	33			2.00 (0.01 to 4.42)	0.0108
GRED		65			1 70 (1 12 to 2 22)	0.0100
Gastritis		65	-		1.19 (1.13 to 2.62)	0.0129
Gu		67			1.11 (0.30 (0 3.42)	0.0017
Dyspepsia		07			1.00 (0.99 (0 1.01)	0.0425
IBS OD		07		_	1.29 (0.07 (0 1.92)	0.2040
	IVVV	00			4.31 (1.00 to 18.61)	0.0500
	IVVV	65			0.84 (2.23 to 20.99)	0.0008
IBD .	IVVV	67			1.01 (1.00 to 1.02)	0.0026
Colon cancer	IVVV	65			3.52 (0.87 to 14.14)	0.0765
Diverticular disease	IVVV	67			1.01 (0.98 to 1.04)	0.3919
Duodenitis	IVW	65		→ 1	1.53 (0.45 to 5.19)	0.4993
Constipation	IVW	65			0.57 (0.21 to 1.55)	0.2715
Fatty liver disease	IVW	65			1.81 (0.95 to 3.45)	0.0730
Cholelithiasis	IVW	65			2.03 (1.08 to 3.80)	0.0269
Acute pancreatitis	IVW	65			0.56 (0.16 to 2.03)	0.3799
Acute appendicitis	IVW	65			0.84 (0.29 to 2.48)	0.7561
Peritonitis	IVW	57			1.00 (1.00 to 1.01)	0.7005
DU	IVW	66			1.00 (0.99 to 1.01)	0.8545
Polyp of colon	IVW	67			1.00 (1.00 to 1.01)	0.1265
Cholecystitis	IVW	66			1.00 (1.00 to 1.01)	0.1407
Inguinal hernia	IVW	66	•		1.00 (0.98 to 1.01)	0.7753
Oesophagitis	IVW	67	•		1.01 (1.00 to 1.02)	0.1127
Primary biliary cholangitis	IVW	27	,		8.70 (0.85 to 89.42)	0.0688
			0.8 1	1.3		
		Fro	tective factors Ri	isk factors		

IVW 9 0.98 (0.96 to 1.	0.0893
IVW 7 🏟 0.99 (0.98 to 1.	01) 0.5991
IVW 50 0.99 (0.98 to 1.	00) 0.0177
IVW 5 1.00 (0.97 to 1.	04) 0.8385
ases	
IVW 39 1.00 (1.00 to 1.	01) 0.4461
IVW 7 1.00 (0.99 to 1.	01) 0.8750
IVW 17 0.99 (0.99 to 1.	00) 0.1104
ases	
IVW 5 1.04 (0.89 to 1.	22) 0.6071
IVW 6 1.00 (1.00 to 1.	00) 0.8992
IVW 8 1.00 (0.99 to 1.	00) 0.5062
IVW 11 1.00 (1.00 to 1.	00) 0.8021
itis IVW 17 🕴 1.00 (1.00 to 1.	01) 0.4904
IVW 10 1.16 (0.89 to 1.	53) 0.2738
0.8 1 1.3	
Crotostivo factora Dick factora	
IVW 9 0.98 (0.96 to 1. IVW 7 0.99 (0.98 to 1. IVW 50 0.99 (0.98 to 1. IVW 50 0.99 (0.97 to 1. ases 1.00 (1.00 to 1. IVW 7 1.00 (0.99 to 1. IVW 7 0.99 (0.98 to 1. IVW 7 1.00 (1.00 to 1. IVW 7 1.00 (0.99 to 1. IVW 17 0.99 (0.99 to 1. IVW 6 1.00 (1.00 to 1. IVW 8 1.00 (1.00 to 1. IVW 11 1.00 (1.00 to 1. IVW 10 1.00 (1.00 to 1. IVW 10 0.8 1 1.3 Protective factors Risk factors	00) 0.08 01) 0.59 00) 0.01 04) 0.83 01) 0.44 01) 0.47 00) 0.11 22) 0.60 00) 0.89 00) 0.89 00) 0.50 00) 0.80 00) 0.80 00) 0.80 00) 0.80 00) 0.80 00) 0.80 00) 0.80 00) 0.80 00) 0.80 00) 0.80 01) 0.49